Previous 10 | Next 10 |
2023-03-23 16:06:31 ET Heron Therapeutics press release ( NASDAQ: HRTX ): Q4 GAAP EPS of -$0.17 beats by $0.15 . Revenue of $30.03M (+45.4% Y/Y) beats by $2.79M . As of December 31, 2022, Heron had cash, cash equivalents and short-term investments of ...
Heron Therapeutics Announces Financial Results for the Three and Twelve Months Ended December 31, 2022 and Highlights Recent Corporate Updates PR Newswire - Annual Net Product Sales Across the Company Grew 25% to $107.7 million in 2022, Compared to Annual Net Product Sales...
2023-03-22 17:35:12 ET Heron Therapeutics ( NASDAQ: HRTX ) is scheduled to announce Q4 earnings results on Thursday, March 23rd, after market close. The consensus EPS Estimate is -$0.36 (+33.3% Y/Y) and the consensus Revenue Estimate is $27.24M (+31.8% Y/Y). Over the l...
2023-03-22 17:35:12 ET Major earnings expected after the bell on Thursday include: Ideanomics ( IDEX ) Planet 13 Holdings ( OTCQX:PLNHF ) Spruce Power Holding Corporation ( SPRU ) Heron Therapeutics ( HRTX ) ADMA Biologics ( ADMA ) For further...
2023-03-18 14:15:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2023-03-16 18:45:17 ET Summary BioXcel Therapeutics, Inc. has just released results for the fourth quarter of 2022. Some analysts have expressed doubts about the commercial success of its Igalmi launch. The good growth in forms approved so far makes me very optimistic about th...
Heron Therapeutics Announces Centers for Medicare & Medicaid Services (CMS) Granted Pass-through Payment Status for APONVIE™, Effective April 1, 2023 Heron Therapeutics Announces Centers for Medicare & Medicaid Services (CMS) Granted Pass-through Payment Status for APONVI...
Heron Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 23, 2023 PR Newswire SAN DIEGO , March 10, 2023 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on i...
2023-03-08 22:15:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2023-03-07 14:00:39 ET The following slide deck was published by Heron Therapeutics, Inc. in conjunction with this event. For further details see: Heron Therapeutics (HRTX) presents at 2023 Cowen Conference - Slideshow
News, Short Squeeze, Breakout and More Instantly...
Heron Therapeutics Inc. Company Name:
HRTX Stock Symbol:
NASDAQ Market:
Heron Therapeutics Inc. Website:
Heron Therapeutics to Report Second Quarter 2024 Financial Results On Tuesday, August 6, 2024 PR Newswire SAN DIEGO , July 30, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, today announced that the company...
Heron Therapeutics Announces the Inclusion of ZYNRELEF® as a Qualifying Product Under the Proposed 2025 Non-Opioid Policy for Pain Relief Under the OPPS and the ASC Payment System PR Newswire SAN DIEGO , July 15, 2024 /PRNewswire/ -- Heron Therapeutics, Inc....
Heron Therapeutics Announces Acceptance of the Prior Approval Supplement Application for ZYNRELEF® Vial Access Needle ("VAN") PR Newswire -The U.S. Food and Drug Administration ("FDA") assigned a Prescription Drug User Fee Act ("PDUFA") goal date of September 23, 2024 ...